Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
latest_posts
- 1
Osteoporosis, the silent disease, can shorten your life − here’s how to prevent fractures and keep bones healthy - 2Could the Star of Bethlehem have actually been a comet?
- 3Everyday Seasonal Positions That Compensate Fairly in the US
- 4How to avoid or deal with an outrageous medical bill
- 5IDF confirms Iranian missile fragments hit near Kirya, multiple cars ablaze in Ramat Gan
- Vote in favor of Your #1 4\u00d74 SUVs
- BHP liable for 2015 Brazil mine disaster: UK court
- Iran war pushes Germany's deficit to 4.2% as growth outlook is cut by 50%
- Tech giants accused of not complying with Australian social media ban
- NASA's Apollo 8 moonshot saved 1968. Could Artemis 2 do the same in 2026?
- Astronomers detect rare 'free floating' exoplanet 10,000 light-years from Earth
- The top astronomical discoveries of 2025
- The Strait of Hormuz Isn’t Just an Oil Problem, It’s Now a Food Problem
- Israel says it will keep control over part of southern Lebanon after war with Hezbollah ends
